|
Radiopharmaceutical therapy is rapidly reshaping the treatment landscape in advanced prostate cancer, bringing new opportunities—and new clinical questions—around patient selection, treatment sequencing, safety, mechanism of action, and future integration.
In this exclusive UroToday clinical conversation series, leading experts in medical oncology, radiation oncology, nuclear medicine, and translational science explore the evolving role of radiopharmaceutical therapy across the prostate cancer continuum. Through practical, peer-to-peer discussions, this series examines today’s treatment landscape, the biological and mechanistic distinctions between emerging approaches, real-world considerations for clinical decision-making, and where the next wave of innovation may take the field.
Click to watch the series below.
- Current Landscape and Unmet Needs - Dustin Boothe & Praful Ravi
- Mechanisms and Clinical Considerations - Philip Kantoff, Ken Herrmann & Neil Bander
- Patient Selection and Treatment Sequencing - Tanya Dorff, Neal Shore & Dustin Boothe
- Radiation Safety, Patient Selection, and Clinical Gaps - Tanya Dorff, Neal Shore & Dustin Boothe
- Endpoints, Immunotherapy, and Future Directions - Michael Morris & Rana McKay
- Payloads, Carriers, Targets, and Combinations - Michael Morris & Rana McKay
|
